Clinical Research and Trials for Celiac Disease Patients
Learn about clinical trials to develop new treatments for celiac disease happening in Canada. You can play an important role in advancing research by participating in a clinical trial or study.
This page includes information on trials and studies in the celiac disease field. If you are interested in registering for a trial, use these links to find out if there one right for you.
For a complete listing of Clinical Trials available in Canada, please visit the Government of Canada’s Clinical Trials Database and search “celiac”. https://health-products.canada.ca/ctdb-bdec/index-eng.jsp
Coming soon to Canada: ILLUMINATE-062 Study
The ILLUMINATE-062 Study is coming soon to Canada. We will update this page with more information in the coming weeks, including trial sites and how to apply to see if you qualify.
The ILLUMINATE-062 Study is looking at the safety and effectiveness of an investigational medication designed to break down gluten in the stomach compared with placebo in those with celiac disease who are on a gluten-free diet. The study will evaluate how well the investigational medication reduces celiac-related symptoms and intestinal damage due to gluten exposure. The study medication (investigational or placebo) is an oral pill that should be taken 3 times per week within 15 minutes of the start of a meal. The study has about 7 clinical visits* and total study duration per participant is up to 36 weeks.
Learn more: https://illuminatecd.com/
Learn more about the study from Dr. Daniel Leffler, Senior Medical Director at Takeda Pharmaceuticals, Gastroenterology, in this ‘A Canadian Celiac Podcast’ with host Sue Jennett.
Join a Study! The Canadian Celiac Association is currently recruiting for the following Clinical Trials:
PROACTIVE Celiac Study Now in Canada & the US
Are you still experiencing celiac disease symptoms despite your best efforts to follow a gluten-free diet?
The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015. In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure. You will not be asked to ingest gluten for this study.
PRV-015 has been previously tested in about 250 people in six completed research studies. These studies show that PRV-015 has been well tolerated, and in celiac patients it may reduce inflammation in the intestine and improve the symptoms of celiac disease in those who continue to experience symptoms despite following a gluten-free diet.
Requirements:
- 18-70 years old
- Biopsy-confirmed celiac disease
- On a gluten-free diet for at least the last 12 months
- Still experiencing celiac disease symptoms
Study Site Locations:
- United States (excluding Alaska and Hawaii)
- Canada
Interested?
Visit survey.proactiveceliac.com/r/REFCCA
Use referral code: REFCCA
About the Study Sponsor
Provention Bio, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases.
University of Alberta - Clinical Trial for AGY
*Enrollment to participate in this study has ended.
A study for individuals with celiac disease is open at the University of Alberta. This study is looking to recruit people who are following a gluten-free diet but are still having symptoms. The research is to look at whether a new product, called AGY, can reduce or eliminate the symptoms associated with gluten exposure. The study will also evaluate the safety of AGY and its effect on quality of life.
A previous study of 10 adults treated with AGY for 4 weeks showed encouraging results. The current study will evaluate AGY in a larger group of people.
Eligible participants would need to:
- Be between 10 and 65 years old
- Have medically diagnosed Celiac Disease at least 12 months before study enrollment.
- Experience periodic, mild to moderate, celiac symptoms despite following a gluten free diet for the last 12 months.
- Be willing to complete several questionnaires (some daily), undergo periodic lab work and urine testing
- Not be allergic to eggs
- Either visit the university 6 times over approximately 16 weeks, or participate remotely
- Willing to sign consent/assent and follow all study procedures
If you are interested in learning more about this study, please contact:
Dory Sample at 780-248-5599, dsample@ualberta.ca
